NCT06590402 Anterior Femoral and Adductor Canal Nerve Blocks in Peds Knees
| NCT ID | NCT06590402 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Hospital for Special Surgery, New York |
| Condition | Anterior Cruciate Ligament Reconstruction |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-06-06 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2025-06-06 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot clinical trial is to compare anterior femoral cutaneous nerve block (AFCN) to adductor canal block ACB) for pediatric patients undergoing either anterior cruciate ligament (ACL) or medial patellofemoral ligament (MPFL). The aims of this trial are: * To measure postoperative functional outcomes in patients who received AFCNB vs. ACB. * To calculate postoperative opioid requirements in pediatric knee surgeries that received AFCNB vs. ACB. * To calculate pain intensity levels at rest and with ambulation in patients who received AFCNB vs. ACB. * To quantify sensory deficits in patients who received AFCNB vs. ACB. * To assess patient-reported outcome measures (e.g., pain expectation scale, pain management satisfaction, PROMIS Pediatric Short Form v1.0 - Physical Activity, PROMIS Scale v1.2 - Global Health) in patients 8-18 years of age who received AFCNB vs. ACB. Subjects undergoing ACL procedures will be compared between those who received the adductor canal block to those who received the anterior femoral cutaneous nerve block. The researchers will also compare individuals who underwent MPFL procedures and received an anterior femoral cutaneous nerve block with those who received the adductor canal block. Participants will: * Be randomized to receive either the AFCNB or ACB in addition to standard of care analgesia. * Maintain a patient diary to document daily pain meds/pain scores * Complete follow up surveys/questionnaires via telephone and during their office visits with surgeons.
Eligibility Criteria
Inclusion Criteria: * 8-18 years old at the time of surgery * Patients 40kg and above * ACL reconstruction of MPFL reconstruction surgery with participating surgeons Exclusion Criteria: * revision surgery * bilateral surgery * general anesthesia * contraindications to any part of the study protocol * relevant pre-existing neurological deficit * chronic pain
Contact & Investigator
Kathryn DelPizzo, MD
PRINCIPAL INVESTIGATOR
Hospital for Special Surgery, New York
Frequently Asked Questions
Who can join the NCT06590402 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 18 Years, studying Anterior Cruciate Ligament Reconstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06590402 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06590402 currently recruiting?
Yes, NCT06590402 is actively recruiting participants. Contact the research team at popovicm@hss.edu for enrollment information.
Where is the NCT06590402 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06590402 clinical trial?
NCT06590402 is sponsored by Hospital for Special Surgery, New York. The principal investigator is Kathryn DelPizzo, MD at Hospital for Special Surgery, New York. The trial plans to enroll 60 participants.